Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-P3 PET/CT for PSMA Expression in Prostate Cancer
NCT05940259Recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-P3 in prostate cancer (PCa), sponsored by Peking University First Hospital. Primary endpoints: The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate at 1 year and The detection efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate at 1 year. Started May 2023; status: recruiting.
02
Drugs
68Ga-P3
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05940259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940259.